166 related articles for article (PubMed ID: 37684534)
1. Crystal Structures of Plk1 Polo-Box Domain Bound to the Human Papillomavirus Minor Capsid Protein L2-Derived Peptide.
Jung S; Lee HS; Shin HC; Choi JS; Kim SJ; Ku B
J Microbiol; 2023 Aug; 61(8):755-764. PubMed ID: 37684534
[TBL] [Abstract][Full Text] [Related]
2. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks.
Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY
Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535
[TBL] [Abstract][Full Text] [Related]
3. Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.
Chen J; Wang D; Wang Z; Wu K; Wei S; Chi X; Qian C; Xu Y; Zhou L; Li Y; Zhang S; Li T; Kong Z; Wang Y; Zheng Q; Yu H; Zhao Q; Zhang J; Xia N; Li S; Gu Y
J Virol; 2023 Mar; 97(3):e0181922. PubMed ID: 36815785
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
6. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
7. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
8. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
9. Structural analysis of the polo-box domain of human Polo-like kinase 2.
Kim JH; Ku B; Lee KS; Kim SJ
Proteins; 2015 Jul; 83(7):1201-8. PubMed ID: 25846005
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
11. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
[TBL] [Abstract][Full Text] [Related]
13. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
14. Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum.
Morante AV; Baboolal DD; Simon X; Pan EC; Meneses PI
Microbiol Spectr; 2022 Jun; 10(3):e0150522. PubMed ID: 35608352
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
16. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
17. Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).
Johnson TM; Antrobus R; Johnson LN
Biochemistry; 2008 Mar; 47(12):3688-96. PubMed ID: 18298087
[TBL] [Abstract][Full Text] [Related]
18. [Virological and carcinogenic aspects of HPV].
Prétet JL; Charlot JF; Mougin C
Bull Acad Natl Med; 2007 Mar; 191(3):611-23; discussion 623. PubMed ID: 18072657
[TBL] [Abstract][Full Text] [Related]
19. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
[TBL] [Abstract][Full Text] [Related]
20. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
